Health & Biotech
ASX Health Stocks: ACCC shoots down merger between pathology stocks ACL and Healius
Health & Biotech
Check Up: Introducing the Brain Atlas, the largest map of the human brain. And recent ASX biotech winners
Health & Biotech
AdAlta on track for trial readout in Q1 2024 after $1.65m cap raise
Health & Biotech
ASX Health Stocks: Mach7 signs $10m deal; Volpara agrees to $300m takeover from South Korean outfit
Health & Biotech
Argenica on track to commence patient dosing for Phase 2 stroke clinical trial in Q1
Health & Biotech
ASX Health Stocks: Patrys to commence Phase 1 trial as drug production process put in motion
Health & Biotech
Prominent Perth fundie the main backer in PharmAust’s $3.5m cap raise
Health & Biotech
Melodiol’s FY23 revenue exceeds $20m as acquisition strategy proves successful
Health & Biotech
ASX Health Stocks: Island Pharma advances anti-viral study; Compumedics scores $9.3m order in China
Health & Biotech
Which companies could make the gains amid a pumping global fitness sector?
Health & Biotech
ASX Health Stocks: The secret is out – Chemist Warehouse plans ASX listing via Sigma healthcare merger
Health & Biotech
InteliCare inks multi-million dollar binding reseller agreement and aged care deployment
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.